The present invention provides a platform technology for testing, screening, selecting and evaluating antibiotics by using genetically engineered strains with identified, individual or combined, resistance mechanisms, prepared from fully susceptible clinical isolates. This antibiotic testing and screening system of the present invention can efficiently and effectively evaluate antibiotics against specified resistance mechanisms in vitro and in vivo, and is suitable on the novel antibiotic development in against multidrug-resistant bacteria.

An immuno-chromatographic diagnosis means for detecting and/or quantifying a plurality of analytes present in an essentially liquid sample, comprising: at least one reaction mixture containing recognition biological molecules and/or competitive ligands labelled with at least one visualisation molecule which is detectable in fluorescence, the reaction mixture being present in a separate container of the recovery system; and at least one recovery system in the form of a solid support to which are bonded competitive ligands and/or recognition biological molecules at distinct and known recovery locations, which are arranged according to a two-dimensional matrix arrangement defined according to a system of coordinates, so as to identify by the localisation of the recovery locations on the support, the analytes present in the sample.

Some embodiments of the disclosure provide a time-resolved fluorescent immunochromato-graphic test strip for detecting vancomycin as well as a preparation method and application thereof. In some embodiments, the test strip includes a bottom plate and a sample absorption pad. A fluorescent microsphere pad, a nitrocellulose membrane coated with a vancomycin-carrier protein conjugate, and an absorbent pad are sequentially overlapped and pasted on the bottom plate. The fluorescent microsphere pad is sprayed with a fluorescent microsphere-labeled vancomycin monoclonal antibody, and the vancomycin monoclonal antibody is prepared by using a vancomycin-bovine serum albumin conjugate as an immunogen.

The present invention relates to antibodies for use in detecting polymyxins and tracers; and to a single-capture immunodetection method and kits, each utilising the antibodies of the invention, and disclosed tracers.

The present disclosure discloses a lincosamides universal monoclonal antibody hybridoma cell strain and application thereof, and belongs to the technical field of food safety immunological detection. According to the present disclosure, a clindamycin chlorine-substituted derivative is used as a hapten, the hapten is coupled with bovine serum albumin (BSA) by an activated ester method to obtain an immunizing antigen, and after being uniformly mixed with a Freund's adjuvant, the immunizing antigen is subcutaneously injected to immunize BALB/c mice; clindamycin is coupled with ovalbumin (OVA) by a carbonyl diimidazole (CDI) method to be used as a coating antigen used for detecting mouse serums and a cell supernatant. The spleen cells of the immunized mice are fused with mouse myeloma cells by a PEG method, and screened by indirect ELISA and indirect competitive ELISA and subcloned three times to obtain a population-selective hybridoma cell strain. The cell strain provided by the present disclosure has relatively good inhibition on clindamycin, lincomycin and pirlimycin, and can meet the demand for lincosamides multi-residue immunoassay products on the market.

Disclosed is a method and apparatus for determining a concentration of a glycopeptide antibiotic containing a phenol moiety such as Vancomycin in a complex sample matrix by extracting the glycopeptide antibiotic from a metered portion of the complex sample matrix by exposing said metered portion to an extraction material having an affinity with the glycopeptide antibiotic; and exposing the extraction material to a metered portion of an eluent for releasing the glycopeptide antibiotic from the extraction material; and by determining a concentration of the glycopeptide antibiotic by adding a Gibbs reagent (2,6 dichloroquinone-4-chloroimide) to the metered portion of the complex sample matrix or the eluent; activating the Gibbs reagent and, after the reaction between the activated Gibbs reagent and the antibiotic has stabilized; detecting the reaction product of the activated Gibbs reagent and the antibiotic in said eluent; and determining the concentration of the antibiotic in the complex sample matrix from the detected reaction product. A method of designing a personalized drug administration regime using the thus obtained concentration is also disclosed.

Embodiments of the present disclosure present novel systems, devices and methods for an automated biological sample analysis using mass-spectrometry. The time from sample introduction to the reporting of data, in some embodiments, takes a relatively short amount of time (e.g., several minutes). In some embodiments, a biological sample to be analyzed is a blood sample. For many applications, only a single drop of blood may be sufficient. Through the use of a mixture of standards with unique molecular mass, a quantitative analysis of the target analyte can be performed in a single MS run (for example), eliminating the need to create and analyze standard curves. One advantage of such embodiments may be that the system, devices, and methods can eliminate the need for batch creation since the requirement to amortize the time and effort of creating and analyzing standard curves can be eliminated.

Provided herein are highly modular and sensitive biosensors for small molecule detection using CRISPR/C as enzymes having collateral single-stranded nucleic acid cleavage activity. Also provided herein are uses of the biosensors in detection platforms for convenient, low-cost assessment of safety and purity of consumable samples, environmental samples, and agricultural products.

Immuno-chromatographic diagnosis means (1) for detecting and/or quantifying a plurality of analytes present in an essentially liquid sample (E), comprising: at least one reaction mixture (2) containing recognition biological molecules and/or competitive ligands labelled with at least one visualisation molecule which is detectable in fluorescence, said reaction mixture being present in a separate container of said recovery system (3); and at least one recovery system (3) in the form of a solid support to which are bonded competitive ligands and/or recognition biological molecules at distinct and known recovery locations (4 and 5), which are arranged according to a two-dimensional matrix arrangement defined according to a system of coordinates, so as to identify by the localisation of said recovery locations (4 and 5) on said support, said analytes present in said sample (E).

Among other things, motility of at least one individual microorganism or a change in motility of at least one individual microorganism or both is or are characterized. The characterized motility or change in motility is used to detect the presence or count of the at least one individual microorganism, or determine the identity of a species or strain of the at least one individual microorganism, or determine a susceptibility of the at least one individual microorganism to one or more antibiotics or other antimicrobials.